홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

바레니클린

5,8,14-Triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2,4,6,8,10-pentaene

HCID 170361
새 반응
인쇄

데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다

기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
249296-44-4
표준 SMILES
c1cnc2cc3c(cc2n1)C1CNCC3C1
InChIKey
JQSHBVHOMNKWFT-UHFFFAOYSA-N
분자식
C13H13N3
평균 분자량
211.26 g/mol
단동위원소 질량
211.11094743

개요

Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor. In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A full agonism was displayed on alpha7-receptors. On March 9, 2015, the U.S. Food and Drug Administration warned that Varenicline, in the form of Pfizer Inc's quit-smoking drug, Chantix, has been associated with seizures and that some patients who drink while taking the drug may become aggressive or black out. Pfizer is conducting an additional safety study of the drug, results of which are expected in late 2015. The FDA said it is keeping the black box in place at least until the results of the trial are announced.

이름 및 식별자

우선 이름
5,8,14-Triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2,4,6,8,10-pentaene
IUPAC
5,8,14-triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2,4,6,8,10-pentaene
현지명
바레니클린
영어명
Varenicline
분자식
C13H13N3
분자량
211.26

이름 및 동의어

5,8,14-triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2,4,6,8,10-pentaeneAB01568242_01Varenicline (INN)5,8,14-triazatetracyclo[10.3.1.0^{2,11}.0^{4,9}]hexadeca-2(11),3,5,7,9-pentaeneNCGC00247735-01NCGC00247735-02VareniclinVarenicline?SCHEMBL225687CHEMBL556954orb1690005SCHEMBL29363551
이름 더 보기
바레니클린ChantixVarenciline10-tetrahydro-Varenicline free base7,8,9,10-tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxaline(1R,12S)-5,8,14-triazatetracyclo[10.3.1.0^{2,11}.0^{4,9}]hexadeca-2,4(9),5,7,10-pentaeneCS-861Hsdb 7591Cp 526555VARENICLINE
7,8,9,10-tetCP 526555; Champix; ChantixHMS5087H05BDBM50166908s6985T4246LAKOS005145561CS-0396

데이터베이스 식별자

물성

구조 계산 물성보충 중

XLogP
0.8
극성 표면적
37.8 Ų
수소 결합 공여자 수
1
수소 결합 수용자 수
3
회전 가능 결합 수
0
무거운 원자 수
16
형식 전하
0
복잡도
254

물리화학적 성질

녹는점
138.5 °C · 138.5 °C
끓는 점
400.6 · 400.6±40.0 °C(Predicted)
밀도
1.247 · 1.247±0.06 g/cm3(Predicted)
저장 조건
-20 °C · Store at -20°C
용해도
DMSO에 용해됨
물리적 상태
가루
산도 계수 (pKa)
9.6 · 9.60±0.20(Predicted)
색상
Light yellow to yellow
BCS Class
1 · 1
안정성
흡습성
InChI
InChI=1S/C13H13N3/c1-2-16-13-5-11-9-3-8(6-14-7-9)10(11)4-12(13)15-1/h1-2,4-5,8-9,14H,3,6-7H2
InChIKey
JQSHBVHOMNKWFT-UHFFFAOYSA-N
SMILES
N1CC2CC(C3=CC4=NC=CN=C4C=C32)C1

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

안전 데이터

유해 물질 데이터
249296-44-4(Hazardous Substances Data)

화학 및 산업

약리 정보

Protein BindingLess than 20%.
PharmacodynamicsVarenicline is a partial nicotinic acetylcholine receptor agonist, designed to partially activate this system while displacing nicotine at its sites of action in the brain.
Mechanism of Action · 1건

Varenicline is an alpha-4 beta-2 neuronal nicotinic acetylcholine receptor partial agonist. The drug shows high selectivity for this receptor subclass, relative to other nicotinic receptors (>500-fold alpha-3 beta-4, >3500-fold alpha-7, >20,000-fold alpha-1 beta gamma delta) or non-nicotinic receptors and transporters (>2000-fold). The drug competitively inhibits the ability of nicotine to bind to and activate the alpha-4 beta-2 receptor. The drug exerts mild agonistic activity at this site, though at a level much lower than nicotine; it is presumed that this activation eases withdrawal symptoms.

Biological Half-LifeThe elimination half-life of varenicline is approximately 24 hours
Metabolism/MetabolitesMetabolism is limited (<10%). Most of the active compound is excreted by the kidneys (81%). A minor amount of varenicline is glucuronidated, oxidated, N-formylated, as well as conjugated to form a hexose.
Absorption, Distribution and Excretion · 1건

Varenicline undergoes minimal metabolism, with 92% excreted unchanged in the urine. Renal elimination of varenicline is primarily through glomerular filtration along with active tubular secretion possibly via the organic cation transporter, OCT2.

응용 분야 · 2건

개요Varenicline, a partial agonist of the a4b2 nicotinic receptor, is a first-in-class drug launched by Pfizer as an aid to smoking cessation treatment. Varenicline exhibits dual action by decreasing craving and withdrawal symptoms, and by decreasing the reinforcement associated with smoking. The addictive properties of nicotine are thought to be mediated in part through its action as an agonist at α4β2 neuronal nicotinic acetylcholine receptors (nAChRs). Activation of α4β2 receptors by nicotine increases the release of dopamine in the mesolimbic system, an effect that is shared by most drugs of abuse. As nicotine levels decrease, dopamine levels decline, which in turn stimulates the urge to smoke. Additionally, a reduced dopaminergic tone due to abstinence from smoking stimulates craving and the withdrawal syndrome. A partial agonist of α4β2 receptors such as varenicline is expected to elicit a moderate and sustained increase in dopamine levels to relieve craving and withdrawal symptoms. In addition, by competitively binding to a4b2 receptors and inhibiting nicotineinduced dopaminergic activation, a partial agonist could attenuate the pharmacologic reward associated with smoking.

관련 반응

12건
반응 기록 만들기
HRID 914732 반응식
HRID 914732생성물로반응물로
HRID 914733 반응식
HRID 914733반응물로
HRID 1665791 반응식
HRID 1665791반응물로
HRID 1665792 반응식
HRID 1665792생성물로
HRID 1665793 반응식
HRID 1665793생성물로
HRID 1665794 반응식
HRID 1665794생성물로
HRID 1879292 반응식
HRID 1879292반응물로
HRID 2092910 반응식
HRID 2092910반응물로
이전1 / 2 페이지

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
CAS
249296-44-4
PubChem CID
170361
DTXSID
DTXSID70891447
Nikkaji
J2.566.151F

용도Varenicline is a useful medication for smoking cessation.

상·하류 제품 정보

하류 제품

Varenicline tartrate

추가 설명

정의ChEBI: An organic heterotetracyclic compound that acts as a partial agonist for nicotinic cholinergic receptors and is used (in the form of its tartate salt) as an aid to giving up smoking.